Antibody discovery platform Immunocan closes RMB250 million Series A
Shanghai-based Immunocan has closed a RMB250 million Series A round led by Vivo Capital, with participation from Gold Mine Multi Family Office and follow-on backing from existing investors including Kingray Capital and TigerYeah Capital. The company said the funds will be used to advance its gene-edited animal platforms, commercialize its fully human antibody rabbit platform, build an AI-driven antibody drug screening platform, and expand its team. Founded in 2020, Immunocan
Immunocan, a Shanghai-based biotechnology firm, has successfully secured RMB250 million in Series A funding. The investment round was spearheaded by Vivo Capital, with contributions from Gold Mine Multi Family Office and existing investors like Kingray Capital and TigerYeah Capital. The company plans to allocate these resources towards enhancing its gene-edited animal models, commercializing its human antibody rabbit platform, and developing an AI-powered antibody drug screening system. Additionally, the funding will support team expansion.
This funding will accelerate Immunocan's development of novel antibody therapies, potentially leading to new treatments for various diseases.
📌 Kaynak
Bu özet TechNode kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →